Home > Treatment Options > Tumor Suppressors > Clinical Trials >
Cetuximab (Erbitux™)
Last Updated: 11/4/18
Status: Potential NF2 Clinical Trial
Index
- Additional Information
- Side Effects
- Other Uses
| Other Names | Erbitux™, Anti EGFR, IMC-C225 |
|---|---|
| Pharmaceutical Companies | Bristol Myers Squib, Merck Serono and Eli Lilly and Company |
| Treatment By | IV |
| Molecular Formula | C6484H10042N1732O2023S36 |
| Drug Bank | DB00002 |
| Inhibitor | Epidermal Growth Factor Receptor (EGFR) Inhibitor |
| Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions. |
1. Additional Information
Due to cardiac arrest prevention, pretreatment with diphenhydramine 30-60 min. before administration is standard of care.
2. Possible Side Effects
Common
- Fevers
- Chills
- Rigors
- Urticaria
- Pruritis
- Rash
- Hypotension
- Bronchospasm
- Dyspnea
- Wheezing
- Angioedema
- Dizziness
- Anaphylaxis
- Cardiac Arrest
Uncommon
- Photosensitivity
- Hypomagnesemia due to Magnesium Wasting
- Pulmonary and Cardiac Toxicity
3. Other Uses
- Head Cancer
- Neck Cancer
- Colorectal Cancer
